These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Pulmonary thromboembolism in lung surgery: use of unfractionated heparin. Yoshida J; Inoue M; Furugaki K; Oyama M; Oozono K Asian Cardiovasc Thorac Ann; 2014 Jan; 22(1):46-8. PubMed ID: 24585643 [TBL] [Abstract][Full Text] [Related]
9. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. Büller HR; Davidson BL; Decousus H; Gallus A; Gent M; Piovella F; Prins MH; Raskob G; van den Berg-Segers AE; Cariou R; Leeuwenkamp O; Lensing AW; N Engl J Med; 2003 Oct; 349(18):1695-702. PubMed ID: 14585937 [TBL] [Abstract][Full Text] [Related]
10. The value of monitoring heparin therapy in the prevention of recurrence in patients with venous thromboembolic disease. Hirsh J Thromb Diath Haemorrh Suppl; 1973; 56():181-90. PubMed ID: 4805494 [No Abstract] [Full Text] [Related]
11. Heparin therapy for thromboembolic disorders. A prospective evaluation of 134 cases monitored by the activated coagulation time. Hattersley PG; Mitsuoka JC; King JH JAMA; 1983 Sep; 250(11):1413-6. PubMed ID: 6887462 [TBL] [Abstract][Full Text] [Related]
13. Use of the subcutaneous heparin pump during pregnancy. Barss VA; Schwartz PA; Greene MF; Phillippe M; Saltzman D; Frigoletto FD J Reprod Med; 1985 Dec; 30(12):899-901. PubMed ID: 4078826 [TBL] [Abstract][Full Text] [Related]
14. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. Hull RD; Raskob GE; Pineo GF; Green D; Trowbridge AA; Elliott CG; Lerner RG; Hall J; Sparling T; Brettell HR N Engl J Med; 1992 Apr; 326(15):975-82. PubMed ID: 1545850 [TBL] [Abstract][Full Text] [Related]
15. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Levine MN; Hirsh J; Gent M; Turpie AG; Cruickshank M; Weitz J; Anderson D; Johnson M Arch Intern Med; 1994 Jan; 154(1):49-56. PubMed ID: 8267489 [TBL] [Abstract][Full Text] [Related]
16. Heparin treatment of deep vein thrombosis. Effects and complications after continuous or intermittent heparin administration. Fagher B; Lundh B Acta Med Scand; 1981; 210(5):357-61. PubMed ID: 7039244 [TBL] [Abstract][Full Text] [Related]
17. Sources of error in heparin therapy of thromboembolic disease. Hattersley PG; Mitsuoka JC; King JH Arch Intern Med; 1980 Sep; 140(9):1173-5. PubMed ID: 7406615 [TBL] [Abstract][Full Text] [Related]
18. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Monreal M; Lafoz E; Olive A; del Rio L; Vedia C Thromb Haemost; 1994 Jan; 71(1):7-11. PubMed ID: 8165649 [TBL] [Abstract][Full Text] [Related]
19. Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism. Prandoni P; Carnovali M; Marchiori A; Arch Intern Med; 2004 May; 164(10):1077-83. PubMed ID: 15159264 [TBL] [Abstract][Full Text] [Related]
20. [Heparin-induced hemorrhage in the treatment of venous thromboembolism]. Monreal M; Casals A; Las Heras G; Roncalés J; Callejas JM; Martorell A; Lisbona C Angiologia; 1990; 42(1):11-5. PubMed ID: 2321800 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]